APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA-Targeted Small Molecule Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global RNA-Targeted Small Molecule Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

4 January 2026196 pages

Choose your research edition.

Industry ResearchRNA-Targeted Small Molecule Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-Targeted Small Molecule Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal RNA-Targeted Small Molecule Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-Targeted Small Molecule Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-Targeted Small Molecule Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global RNA-Targeted Small Molecule Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of RNA-Targeted Small Molecule Drugs include Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics and Expansion Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global RNA-Targeted Small Molecule Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNA-Targeted Small Molecule Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNA-Targeted Small Molecule Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the RNA-Targeted Small Molecule Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

RNA-Targeted Small Molecule Drugs Segment by Company

Roche

Novartis

PTC Therapeutics

Biogen

Accent Therapeutics

Anima Biotech

Arrakis Pharmaceuticals

Epics Therapeutics

Expansion Therapeutics

Gotham Therapeutics

H3 Biomedicine

Ribometrix

Skyhawk Therapeutics

STORM Therapeutics

Twentyeight-Seven Therapeutics

RNA-Targeted Small Molecule Drugs Segment by Type

mRNA Translation Regulation

RNA Splicing Modification

Direct RNA Targeting

Indirect RNA Targeting - Epitranscriptomics

RNA-Targeted Small Molecule Drugs Segment by Application

SMA

Oncology

Lung Fibrosis

Huntington's Disease

Others

RNA-Targeted Small Molecule Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecule Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecule Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecule Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of RNA-Targeted Small Molecule Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNA-Targeted Small Molecule Drugs industry.

Chapter 3: Detailed analysis of RNA-Targeted Small Molecule Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNA-Targeted Small Molecule Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of mRNA Translation Regulation Table 3. Key Players of RNA Splicing Modification Table 4. Key Players of Direct RNA Targeting Table 3. Key Players of Indirect RNA Targeting - Epitranscriptomics Table 4. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of SMA Table 6. Key Players of Oncology Table 7. Key Players of Lung Fibrosis Table 8. Key Players of Huntington's Disease Table 9. Key Players of Others Table 10. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2021-2026) & (US$ Million) Table 12. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2021-2026) Table 13. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2027-2032) & (US$ Million) Table 14. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2027-2032) Table 15. RNA-Targeted Small Molecule Drugs Industry Trends Table 16. RNA-Targeted Small Molecule Drugs Industry Drivers Table 17. RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges Table 18. RNA-Targeted Small Molecule Drugs Industry Restraints Table 19. Global RNA-Targeted Small Molecule Drugs Revenue by Company (US$ Million) & (2021-2026) Table 20. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Company (2021-2026) Table 21. Global RNA-Targeted Small Molecule Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global RNA-Targeted Small Molecule Drugs Key Company Head Office and Area Served Table 23. Global RNA-Targeted Small Molecule Drugs Company, Product Type & Application Table 24. Global RNA-Targeted Small Molecule Drugs Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global RNA-Targeted Small Molecule Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global RNA-Targeted Small Molecule Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026) & (US$ Million) Table 29. Global RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032) & (US$ Million) Table 30. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2021-2026) Table 31. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2027-2032) Table 32. Global RNA-Targeted Small Molecule Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026) & (US$ Million) Table 34. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032) & (US$ Million) Table 35. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2021-2026) Table 36. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2027-2032) Table 37. Roche Company Information Table 38. Roche Business Overview Table 39. Roche RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Roche RNA-Targeted Small Molecule Drugs Product Portfolio Table 41. Roche Recent Development Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Novartis RNA-Targeted Small Molecule Drugs Product Portfolio Table 46. Novartis Recent Development Table 47. PTC Therapeutics Company Information Table 48. PTC Therapeutics Business Overview Table 49. PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 51. PTC Therapeutics Recent Development Table 52. Biogen Company Information Table 53. Biogen Business Overview Table 54. Biogen RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Biogen RNA-Targeted Small Molecule Drugs Product Portfolio Table 56. Biogen Recent Development Table 57. Accent Therapeutics Company Information Table 58. Accent Therapeutics Business Overview Table 59. Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 61. Accent Therapeutics Recent Development Table 62. Anima Biotech Company Information Table 63. Anima Biotech Business Overview Table 64. Anima Biotech RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio Table 66. Anima Biotech Recent Development Table 67. Arrakis Pharmaceuticals Company Information Table 68. Arrakis Pharmaceuticals Business Overview Table 69. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio Table 71. Arrakis Pharmaceuticals Recent Development Table 72. Epics Therapeutics Company Information Table 73. Epics Therapeutics Business Overview Table 74. Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 76. Epics Therapeutics Recent Development Table 77. Expansion Therapeutics Company Information Table 78. Expansion Therapeutics Business Overview Table 79. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 81. Expansion Therapeutics Recent Development Table 82. Gotham Therapeutics Company Information Table 83. Gotham Therapeutics Business Overview Table 84. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 86. Gotham Therapeutics Recent Development Table 87. H3 Biomedicine Company Information Table 88. H3 Biomedicine Business Overview Table 89. H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio Table 91. H3 Biomedicine Recent Development Table 92. Ribometrix Company Information Table 93. Ribometrix Business Overview Table 94. Ribometrix RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio Table 96. Ribometrix Recent Development Table 97. Skyhawk Therapeutics Company Information Table 98. Skyhawk Therapeutics Business Overview Table 99. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 101. Skyhawk Therapeutics Recent Development Table 102. STORM Therapeutics Company Information Table 103. STORM Therapeutics Business Overview Table 104. STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 106. STORM Therapeutics Recent Development Table 107. Twentyeight-Seven Therapeutics Company Information Table 108. Twentyeight-Seven Therapeutics Business Overview Table 109. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 111. Twentyeight-Seven Therapeutics Recent Development Table 112. North America RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026) & (US$ Million) Table 113. North America RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032) & (US$ Million) Table 114. North America RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026) & (US$ Million) Table 115. North America RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032) & (US$ Million) Table 116. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) Table 118. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032) Table 119. Europe RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026) & (US$ Million) Table 120. Europe RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032) & (US$ Million) Table 121. Europe RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026) & (US$ Million) Table 122. Europe RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032) & (US$ Million) Table 123. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) Table 125. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032) Table 126. China RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026) & (US$ Million) Table 127. China RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032) & (US$ Million) Table 128. China RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026) & (US$ Million) Table 129. China RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032) & (US$ Million) Table 130. Asia RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026) & (US$ Million) Table 131. Asia RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032) & (US$ Million) Table 132. Asia RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026) & (US$ Million) Table 133. Asia RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032) & (US$ Million) Table 134. Asia RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Asia RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) Table 136. Asia RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032) Table 137. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026) & (US$ Million) Table 138. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032) & (US$ Million) Table 139. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026) & (US$ Million) Table 140. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032) & (US$ Million) Table 141. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) Table 143. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032) Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. RNA-Targeted Small Molecule Drugs Product Image Figure 2. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global RNA-Targeted Small Molecule Drugs Market Share by Type: 2025 VS 2032 Figure 4. mRNA Translation Regulation Image Figure 5. RNA Splicing Modification Image Figure 6. Direct RNA Targeting Image Figure 7. Indirect RNA Targeting - Epitranscriptomics Image Figure 8. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global RNA-Targeted Small Molecule Drugs Market Share by Application: 2025 VS 2032 Figure 10. SMA Image Figure 11. Oncology Image Figure 12. Lung Fibrosis Image Figure 13. Huntington's Disease Image Figure 14. Others Image Figure 15. Global RNA-Targeted Small Molecule Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 17. Global RNA-Targeted Small Molecule Drugs Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global RNA-Targeted Small Molecule Drugs Market Share by Players in 2025 Figure 20. Global Top 5 and 10 RNA-Targeted Small Molecule Drugs Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global RNA-Targeted Small Molecule Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2021-2032) Figure 24. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 27. North America RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032) Figure 28. North America RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032) Figure 29. North America RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 30. United States RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Canada RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 32. Mexico RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 33. Europe RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 34. Europe RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032) Figure 35. Europe RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032) Figure 36. Europe RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 37. Germany RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 38. France RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 39. U.K. RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 40. Italy RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 41. Russia RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 43. China RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 44. China RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032) Figure 45. China RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032) Figure 46. Asia RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 47. Asia RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032) Figure 48. Asia RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032) Figure 49. Asia RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 50. Japan RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 51. South Korea RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 54. India RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 55. Australia RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 60. Brazil RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 61. South Africa RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Turkey RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 64. Argentina RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 65. UAE RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 66. Egypt RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 67. Chile RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA Translation Regulation
  • RNA Splicing Modification
  • Direct RNA Targeting
  • Indirect RNA Targeting - Epitranscriptomics
Applications
  • SMA
  • Oncology
  • Lung Fibrosis
  • Huntington's Disease
  • Others
Companies covered
  • Roche
  • Novartis
  • PTC Therapeutics
  • Biogen
  • Accent Therapeutics
  • Anima Biotech
  • Arrakis Pharmaceuticals
  • Epics Therapeutics
  • Expansion Therapeutics
  • Gotham Therapeutics
  • H3 Biomedicine
  • Ribometrix
  • Skyhawk Therapeutics
  • STORM Therapeutics
  • Twentyeight-Seven Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 mRNA Translation Regulation
  5. 1.2.3 RNA Splicing Modification
  6. 1.2.4 Direct RNA Targeting
  7. 1.2.5 Indirect RNA Targeting - Epitranscriptomics
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 SMA
  11. 1.3.3 Oncology
  12. 1.3.4 Lung Fibrosis
  13. 1.3.5 Huntington's Disease
  14. 1.3.6 Others
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global RNA-Targeted Small Molecule Drugs Growth Trends by Region
  17. 1.5.1 Global RNA-Targeted Small Molecule Drugs Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 RNA-Targeted Small Molecule Drugs Market Size by Region (2021-2026)
  19. 1.5.3 RNA-Targeted Small Molecule Drugs Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global RNA-Targeted Small Molecule Drugs Market Dynamics
  1. 2.1 RNA-Targeted Small Molecule Drugs Industry Trends
  2. 2.2 RNA-Targeted Small Molecule Drugs Industry Drivers
  3. 2.3 RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges
  4. 2.4 RNA-Targeted Small Molecule Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global RNA-Targeted Small Molecule Drugs Revenue by Company (2021-2026)
  2. 3.2 Global RNA-Targeted Small Molecule Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global RNA-Targeted Small Molecule Drugs Key Company Head office and Area Served
  4. 3.4 Global RNA-Targeted Small Molecule Drugs Company, Product Type & Application
  5. 3.5 Global RNA-Targeted Small Molecule Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global RNA-Targeted Small Molecule Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 RNA-Targeted Small Molecule Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 RNA-Targeted Small Molecule Drugs Tier 1, Tier 2, and Tier 3
4 RNA-Targeted Small Molecule Drugs Market by Type
  1. 4.1 Global RNA-Targeted Small Molecule Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2032)
  3. 4.3 Global RNA-Targeted Small Molecule Drugs Market Size Share by Type (2021-2032)
5 RNA-Targeted Small Molecule Drugs Market by Application
  1. 5.1 Global RNA-Targeted Small Molecule Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2032)
  3. 5.3 Global RNA-Targeted Small Molecule Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Roche
  2. 6.1.1 Roche Company Information
  3. 6.1.2 Roche Business Overview
  4. 6.1.3 Roche RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Roche RNA-Targeted Small Molecule Drugs Product Portfolio
  6. 6.1.5 Roche Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Novartis RNA-Targeted Small Molecule Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 PTC Therapeutics
  14. 6.3.1 PTC Therapeutics Company Information
  15. 6.3.2 PTC Therapeutics Business Overview
  16. 6.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  18. 6.3.5 PTC Therapeutics Recent Developments
  19. 6.4 Biogen
  20. 6.4.1 Biogen Company Information
  21. 6.4.2 Biogen Business Overview
  22. 6.4.3 Biogen RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Biogen RNA-Targeted Small Molecule Drugs Product Portfolio
  24. 6.4.5 Biogen Recent Developments
  25. 6.5 Accent Therapeutics
  26. 6.5.1 Accent Therapeutics Company Information
  27. 6.5.2 Accent Therapeutics Business Overview
  28. 6.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  30. 6.5.5 Accent Therapeutics Recent Developments
  31. 6.6 Anima Biotech
  32. 6.6.1 Anima Biotech Company Information
  33. 6.6.2 Anima Biotech Business Overview
  34. 6.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio
  36. 6.6.5 Anima Biotech Recent Developments
  37. 6.7 Arrakis Pharmaceuticals
  38. 6.7.1 Arrakis Pharmaceuticals Company Information
  39. 6.7.2 Arrakis Pharmaceuticals Business Overview
  40. 6.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio
  42. 6.7.5 Arrakis Pharmaceuticals Recent Developments
  43. 6.8 Epics Therapeutics
  44. 6.8.1 Epics Therapeutics Company Information
  45. 6.8.2 Epics Therapeutics Business Overview
  46. 6.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  48. 6.8.5 Epics Therapeutics Recent Developments
  49. 6.9 Expansion Therapeutics
  50. 6.9.1 Expansion Therapeutics Company Information
  51. 6.9.2 Expansion Therapeutics Business Overview
  52. 6.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  54. 6.9.5 Expansion Therapeutics Recent Developments
  55. 6.10 Gotham Therapeutics
  56. 6.10.1 Gotham Therapeutics Company Information
  57. 6.10.2 Gotham Therapeutics Business Overview
  58. 6.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  60. 6.10.5 Gotham Therapeutics Recent Developments
  61. 6.11 H3 Biomedicine
  62. 6.11.1 H3 Biomedicine Company Information
  63. 6.11.2 H3 Biomedicine Business Overview
  64. 6.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio
  66. 6.11.5 H3 Biomedicine Recent Developments
  67. 6.12 Ribometrix
  68. 6.12.1 Ribometrix Company Information
  69. 6.12.2 Ribometrix Business Overview
  70. 6.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio
  72. 6.12.5 Ribometrix Recent Developments
  73. 6.13 Skyhawk Therapeutics
  74. 6.13.1 Skyhawk Therapeutics Company Information
  75. 6.13.2 Skyhawk Therapeutics Business Overview
  76. 6.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  78. 6.13.5 Skyhawk Therapeutics Recent Developments
  79. 6.14 STORM Therapeutics
  80. 6.14.1 STORM Therapeutics Company Information
  81. 6.14.2 STORM Therapeutics Business Overview
  82. 6.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  84. 6.14.5 STORM Therapeutics Recent Developments
  85. 6.15 Twentyeight-Seven Therapeutics
  86. 6.15.1 Twentyeight-Seven Therapeutics Company Information
  87. 6.15.2 Twentyeight-Seven Therapeutics Business Overview
  88. 6.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  90. 6.15.5 Twentyeight-Seven Therapeutics Recent Developments
7 North America
  1. 7.1 North America RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
  2. 7.2 North America RNA-Targeted Small Molecule Drugs Market Size by Type
  3. 7.2.1 North America RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032)
  6. 7.3 North America RNA-Targeted Small Molecule Drugs Market Size by Application
  7. 7.3.1 North America RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032)
  10. 7.4 North America RNA-Targeted Small Molecule Drugs Market Size by Country
  11. 7.4.1 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
  2. 8.2 Europe RNA-Targeted Small Molecule Drugs Market Size by Type
  3. 8.2.1 Europe RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe RNA-Targeted Small Molecule Drugs Market Size by Application
  7. 8.3.1 Europe RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe RNA-Targeted Small Molecule Drugs Market Size by Country
  11. 8.4.1 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
  2. 9.2 China RNA-Targeted Small Molecule Drugs Market Size by Type
  3. 9.2.1 China RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032)
  6. 9.3 China RNA-Targeted Small Molecule Drugs Market Size by Application
  7. 9.3.1 China RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
  2. 10.2 Asia RNA-Targeted Small Molecule Drugs Market Size by Type
  3. 10.2.1 Asia RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia RNA-Targeted Small Molecule Drugs Market Size by Application
  7. 10.3.1 Asia RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia RNA-Targeted Small Molecule Drugs Market Size by Country
  11. 10.4.1 Asia RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst